Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y406-01001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-88 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
filingDate |
2004-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2007-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2007527697-A |
titleOfInvention |
Modified Bordetella adenylate cyclase comprising or lacking the CD11b / CD18 interaction domain and uses thereof |
abstract |
The present invention relates to modified Bordetella adenylate cyclase toxins lacking CD11b / CD18 binding and their use in the manufacture of pharmaceutical compositions for the treatment of whooping cough and / or for protection against Bordetella infection. The present invention also relates to specific fragments of Bordetella adenylate cyclase comprising the CD11b / CD18 interaction domain, and their use to target the cells specifically to CD11b expressing cells. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10751404-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018513218-A |
priorityDate |
2003-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |